Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant

Abstract

s / Biol Blood Marrow Transplant 21 (2015) S127eS146 S142 Conclusions: More than half of patients with int-risk AML in CR1 achieved sustained remissions using autoSCT. Of those who relapse, nearly 50% proceed to alloSCT and 31% are long-term disease-free survivors. Relapse-free survival has likely decreased in the most recent era due to changes in patient selection. AutoSCT remains a reasonable option for int-risk patients with AML in CR1, with outcomes rivaling those currently achieved with alternative donor alloSCT.